Details for Patent: 6,875,872

Summary for Patent: 6,875,872

Title:	Compounds
Abstract:	The novel optically pure compounds Na.sup.+, Mg.sup.2+, Li.sup.+, K.sup.+, Ca.sup.2+ and N.sup.+ (R).sub.4 salts of (+)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H- benzimidazole or (-)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H- benzimidazole, in particular sodium and magnesium salt form thereof, where R is an alkyl with 1-4 carbon atoms, processes for the preparation thereof and pharmaceutical preparations containing the compounds as active ingredients, as well as the use of the compounds in pharmaceutical preparations and intermediates obtained by preparing the compounds.
Inventor(s):	Lindberg; Per Lennart (Molndal, SE), Von Unge; Sverker (Fjaras, SE)
Assignee:	AstraZeneca (Sodertalje, SE)
Application Number:	09/690,044
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 6,875,872
Patent Claim Types: see list of patent claims	Compound;

Drugs Protected by US Patent 6,875,872

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate

Foreign Priority and PCT Information for Patent: 6,875,872

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
Sweden	9301830	May 28, 1993

International Family Members for US Patent 6,875,872

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	1020461		C300482	Netherlands
European Patent Office	1020461		91870	Luxembourg
European Patent Office	1020461		300482	Netherlands
Austria	197452
Australia	676337
Australia	6902494